(Q46890986)

English

Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma

scientific article published on 19 November 2007

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18026153

Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18026153

Isaac Ben-Bassat

9

object named as

I Ben-Bassat

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18026153

author name string

A Shimoni

1

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18026153

S T Zwas

2

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18026153

Y Oksman

3

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18026153

I Hardan

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18026153

N Shem-Tov

5

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18026153

A Rand

6

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18026153

R Yerushalmi

7

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18026153

A Avigdor

8

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18026153

A Nagler

10

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18026153

language of work or name

0 references

publication date

19 November 2007

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18026153

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18026153

41

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18026153

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18026153

355-361

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18026153

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

The graft-versus-lymphoma effect: clinical review and future opportunities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

Radioimmunotherapy of non-Hodgkin lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

Radioimmunotherapy as non-myeloablative conditioning for allogeneic marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

Rituximab for steroid-refractory chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

21 January 2018

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

7 January 2021

based on heuristic

inferred from DOI database lookup

International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

7 January 2021

based on heuristic

inferred from DOI database lookup

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705919

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1705919

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18026153

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18026153

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46890986&oldid=2208218055"